BRPI0513793A - composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma condição em um mamìfero, formulação farmacêutica, e, composição farmacêutica - Google Patents

composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma condição em um mamìfero, formulação farmacêutica, e, composição farmacêutica

Info

Publication number
BRPI0513793A
BRPI0513793A BRPI0513793-4A BRPI0513793A BRPI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A
Authority
BR
Brazil
Prior art keywords
treating
condition
pharmaceutically acceptable
mammal
salt
Prior art date
Application number
BRPI0513793-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark T Bilodeau
Zhicai Wu
John Hartnett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0513793A publication Critical patent/BRPI0513793A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0513793-4A 2004-07-29 2005-07-25 composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma condição em um mamìfero, formulação farmacêutica, e, composição farmacêutica BRPI0513793A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59218104P 2004-07-29 2004-07-29
PCT/US2005/026334 WO2006028590A1 (en) 2004-07-29 2005-07-25 1,1,2,2-tetra (hetero) arylethanes or 1,1,2-tri (hetero) aryl-2-heterocyclylethanes as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
BRPI0513793A true BRPI0513793A (pt) 2008-05-13

Family

ID=35613661

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513793-4A BRPI0513793A (pt) 2004-07-29 2005-07-25 composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma condição em um mamìfero, formulação farmacêutica, e, composição farmacêutica

Country Status (15)

Country Link
KR (1) KR20070043985A (ru)
AR (1) AR049847A1 (ru)
BR (1) BRPI0513793A (ru)
CR (1) CR8876A (ru)
EC (1) ECSP077208A (ru)
IL (1) IL180846A0 (ru)
MA (1) MA28980B1 (ru)
MX (1) MX2007001188A (ru)
NO (1) NO20071107L (ru)
PE (1) PE20060382A1 (ru)
RU (1) RU2344134C2 (ru)
TW (1) TW200607493A (ru)
UA (1) UA88018C2 (ru)
WO (1) WO2006028590A1 (ru)
ZA (1) ZA200700477B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755569A1 (en) * 2009-03-18 2010-09-23 Medicure International Inc. Transdermal pharmaceutical preparation and administration of tirofiban
AU2013274619B2 (en) 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2140865B2 (de) * 1971-08-14 1979-10-11 Bayer Ag, 5090 Leverkusen 1 -Imidazolyl-methanphosphonsäureester, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE19951701A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
DE60322019D1 (de) * 2002-01-04 2008-08-21 Neurosearch As Kaliumkanal-modulatoren

Also Published As

Publication number Publication date
RU2007107408A (ru) 2008-09-10
AR049847A1 (es) 2006-09-06
PE20060382A1 (es) 2006-05-15
NO20071107L (no) 2007-04-19
ECSP077208A (es) 2007-02-28
UA88018C2 (ru) 2009-09-10
CR8876A (es) 2007-08-28
IL180846A0 (en) 2007-06-03
ZA200700477B (en) 2009-08-26
MX2007001188A (es) 2007-03-21
RU2344134C2 (ru) 2009-01-20
KR20070043985A (ko) 2007-04-26
WO2006028590A1 (en) 2006-03-16
MA28980B1 (fr) 2007-11-01
TW200607493A (en) 2006-03-01

Similar Documents

Publication Publication Date Title
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
BRPI0507198A (pt) derivados de bisariluréia
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
BRPI0512193B8 (pt) composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EA201170607A1 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0606793A8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.